中国临床药学杂志2025，Vol.34Issue(2)：81-86,6.DOI:10.19577/j.1007-4406.2025.02.001
La蛋白抑制剂Comp 1120通过53BP1途径增强卵巢癌细胞对卡铂的敏感性
La protein inhibitor Comp 1120 enhances the sensitivity of ovarian cancer cells to carboplatin via the 53BP1 pathway
摘要
Abstract
AIM To explore the role of La protein inhibitor Comp 1120 in enhancing the sensitivity of ovarian cancer cells to carboplatin.METHODS The effect of the combined use of Comp 1120 and carboplatin was evaluated using the A2780 ovarian cancer cell line,with a particular focus on the role of 53BP1 in this process.Cell apoptosis was assessed using Western blot,TUNEL assays,and flow cytometry.RESULTS Western blot analysis showed that in A2780 ovarian cancer cells treated with the combination of carboplatin and Comp 1120,the expressions of pro-apoptotic proteins Caspase-3 and BAX were significantly upregulated(P＜0.01),while the expression of the anti-apoptotic protein Bcl-2 was downregulated(P＜0.01).TUNEL assay and flow cytometry further confirmed that the combination of carboplatin and Comp 1120 significantly promoted cell apoptosis(P＜0.01).All experimental results indicated that this pro-apoptotic effect depended on the expression of 53BP1.The pro-apoptotic effect of the combined treatment was significantly reduced in cells with 53BP1 gene silencing(P＜0.01),suggesting that Comp 1120 enhanced carboplatin sensitivity through 53BP1 regulation.CONCLUSION This study demonstrates that the La protein inhibitor Comp 1120 can effectively enhance the sensitivity of ovarian cancer cells to carboplatin,likely involving modulation of the 53BP1 pathway.关键词
La蛋白/Comp 1120/卵巢癌/卡铂敏感性/53BP1Key words
La protein/Comp 1120/ovarian cancer/carboplatin sensitivity/53BP1分类
药学引用本文复制引用
李俊慜,朱佳蕾,汤静..La蛋白抑制剂Comp 1120通过53BP1途径增强卵巢癌细胞对卡铂的敏感性[J].中国临床药学杂志,2025,34(2):81-86,6.基金项目
中华医学会临床药学分会2023年度临床药学科研基金(编号Z-2021-46-2101-2023) （编号Z-2021-46-2101-2023）
上海市青浦区卫生健康系统第五轮学科带头人培养计划(编号XD2023-10) （编号XD2023-10）
